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ABSTRACT
Objective To summarise the evidence on intra- 
articular therapies (IAT) to inform the 2020 EULAR 
recommendations.
Methods An overview of systematic reviews (SR) 
including randomised- controlled trials (RCTs) of IAT in 
adults with arthropathies was performed up to July 2020. 
Pain, function, and frequency of adverse events were the 
main efficacy and safety outcomes, respectively. Quality 
was assessed with the A MeaSurement Tool to Assess 
Systematic Reviews (AMSTAR)-2 tool.
Results Of 184 references identified, 16 met the inclusion 
criteria, and a search of their reference lists identified 16 
additional SRs. After quality assessment, 29 were finally 
included. Of these, 18 focused on knee osteoarthritis 
(KOA), 6 on hip osteoarthritis (HOA), 3 on shoulder 
capsulitis (SC), and 3 on rheumatoid arthritis. Overall, 
hyaluronic acid showed a small effect on pain and function 
in KOA but not in HOA or shoulder capsulitis. Intra- articular 
glucocorticoids showed a small effect in pain and function 
in KOA and function in HOA and SC. Platelet- rich plasma 
showed benefit in pain and function in KOA but not in 
HOA. Mesenchymal stem cells behaved similarly. Most SR 
results were of moderate quality and RCTs included often 
presented a high risk of bias, mainly due to inadequate 
blinding and heterogeneous results. All interventions were 
well tolerated with no clear safety differences.
Conclusions This overview underlines that most IAT 
currently used in KOA, HOA, and SC exert small effects 
and are well tolerated. However, no firm conclusions can 
be drawn for inflammatory arthritis due to the limited data 
found.
INTRODUCTION
Intra- articular therapies (IAT) have been 
widely used in clinical practice for years to 
reduce joint pain and improve function.1 They 
are used in many joint disorders including 
osteoarthritis (OA) and rheumatoid arthritis 
(RA) and delivered by a range of health 
professionals including clinicians from a 
range of specialities and also allied health-
care professionals.2 3 However, evidence on 
the efficacy and safety of available therapies is 
not always consistent, due in part to methodo-
logical limitations in published trials.4 5
Currently, many compounds are available 
as IAT from glucocorticoids (GC)—methyl-
prednisolone acetate (MPA), triamcinolone 
Key messages
What is already known about this subject?
 ► Intra- articular therapies are frequently used in clini-
cal practice by a wide range of health professionals 
from different specialties.Several compounds are 
currently available for intra- articular administration, 
from glucocorticoids to the more recent platelet- rich 
plasma or mesenchymal stem cells. Nonetheless, 
data on their efficacy in certain diseases are incon-
sistent and a matter of debate.
What does this study add?
 ► This overview of systematic reviews provides a 
summary of the current evidence on the efficacy and 
safety of most compounds commonly used for intra- 
articular injections.
How might this impact on clinical practice or 
future developments?
 ► This overview of systematic reviews informed the 
task force for the 2021 EULAR recommendations for 
intra- articular therapies and constitutes an evidence 
base for future updates
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acetonide (TA), and triamcinolone hexacetonide 
(TH)—radioisotopes—yttrium-90, rhenium-186, etc—or 
hyaluronic acid (HA) to more recent therapies such as 
platelet- rich plasma (PRP) and mesenchymal stem cells 
(MSC), mostly used for treating OA.6–10 The arrival of 
the latter three products on the market was accompanied 
by a vast amount of literature with contradictory results 
that are still under debate. Furthermore, intra- articular 
procedures elicit an important placebo effect, something 
that adds more complexity to its efficacy assessment.5 11–13
As around the world life expectancy, obesity, and 
sedentary lifestyle increase,14–16 the burden of disease 
imposed by chronic arthropathies and their comorbidi-
ties also increases, thus providing the right scenario for 
local treatments such as IAT, while the search for disease- 
modifying osteoarthritic drugs continues.
Based on all this, a task force was assembled by the 
EULAR to produce recommendations for IAT in arthrop-
athies. The objective of the present work was to inform 
the task force about the current state of the evidence.
METHODS
Study design
We performed an overview of systematic reviews (SR) 
following a prespecified protocol. The present study is 
reported following the Preferred Reporting Items for 
Systematic Reviews and Meta- analysis (PRISMA) state-
ment.17
Eligibility criteria
To be eligible, the SR had to include randomised clinical 
trials (RCT) assessing IAT in adults (≥18 years old) with 
any arthropathy, excluding the spine and temporoman-
dibular joints.
Interventions (IAT) could be any of the following: 
GC, HA, PRP, MSC, radiopharmaceuticals, anaesthetics, 
opioids or biologicals. Comparators could be any of the 
above mentioned, any form of intra- articular placebo or 
drugs administered orally as the standard of care (SoC), 
such as paracetamol/acetaminophen, non- steroidal anti- 
inflammatory drugs, pregabalin, tricyclic antidepres-
sants. Studies evaluating botulinum toxin as intervention 
were excluded since its use was deemed to be irrelevant 
to the current clinical practice of the specialities repre-
sented within the task force. Surgical procedures were 
also excluded as comparators since they do not represent 
the SoC in most diseases covered in the current study. 
SRs assessing multiple comparators, including ozone or 
botulinum toxin, were included as long as they presented 
separate comparisons for the interventions mentioned in 
the inclusion criteria.
All efficacy and safety outcomes were considered, 
especially change in pain and function with any avail-
able measure, such as the Visual Analogue Scale (VAS), 
Lequesne index18 or the Western Ontario and McMaster 
Universities Osteoarthritis Index (WOMAC),19 and 
adverse events (AE), including serious adverse events 
(SAE), such as local reactions or swelling for the former 
and infections in the injected joint for the latter.
Search strategy
A search was performed in MEDLINE with the assistance 
of an expert librarian, from inception to January 2019 
and updated in July 2020. The references of the included 
SRs were reviewed, as well as publications provided by 
the members of the task force. Details on the complete 
search strategy are provided in the online supplemental 
material.
Study selection and data collection
Two investigators (SCR- G and RC- M) independently 
screened the titles and abstracts to ascertain eligibility. 
The full texts of the eligible articles were then appraised 
using the same approach, with discrepancies solved 
through consensus, including a third investigator (LC) 
if needed. Data regarding study and population char-
acteristics, inclusion/exclusion criteria, interventions, 
outcome definition, outcome measures, and follow- up 
was extracted using a standardised form.
Methodological quality assessment
The same two investigators performed an independent 
quality assessment of the eligible SRs using the ‘A MeaS-
urement Tool to Assess Systematic Reviews (AMSTAR)−2’ 
tool.20 Briefly, this instrument rates the overall confi-
dence in the results of a given SR by thoroughly analysing 
seven critical domains. The quality was used as a crite-
rion for inclusion. Only SRs of high or moderate quality 
were included unless a low quality focused on a disease 
or intervention not covered by the already included SRs.
Data analysis
The qualitative synthesis was carried out by disease and 
compound. For binary variables, we extracted the ORs 
or risk ratios (RR) with their 95% CI. For continuous 
outcomes, data were retrieved as mean difference (MD) 
with 95% CI. When different measurements were used 
for the same outcome, treatment effects were retrieved as 
standardised mean difference (SMD) with CI. To inter-
pret the magnitude of the effects, we used the criteria 
proposed by Cohen.21
RESULTS
From a total of 183 references, after removing duplicates, 
62 were selected for full- text review and 16 met inclusion 
criteria. Additionally, 16 SRs were identified through the 
reference lists of included studies and after an update 
to July 2020. Hence, 32 SRs underwent quality assess-
ment. Three SRs were rated as of ‘high confidence’, 18 
as ‘moderate’, 8 as ‘low’, and 3 as ‘critically low confi-
dence’. Following the prespecified protocol, the latter 
were excluded. Those rated as of low confidence were 
finally included due to the low amount of data on the 
studied compounds. Therefore, 29 SRs were included in 
the qualitative synthesis. A flowchart is shown in figure 1 
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and a list of excluded articles with reasons for exclusion is 
provided in the online supplemental material.
The main features of the SRs included are summarised 
in table 1. Knee osteoarthritis (KOA) was analysed in 18 
SRs,4–7 22–35 hip OA in 6,36–42 shoulder adhesive capsulitis 
in 3,43–45 and RA in 3.34 46 47 One SR analysed the efficacy 
of IAT in both KOA and RA.34 Different HA- containing 
compounds were assessed in 13 SR,4–7 22 30 31 33 35 37 40 44 47 
PRP in 8,25–27 29 32 36 39 41 42 GC in 6,23 28 34 38 43 45 and MSC 
and yttrium synovectomy in 1 each.24 46
Efficacy of intra-articular treatments
Knee osteoarthritis
The main efficacy results are shown in table 2. The most 
frequent outcomes were pain, function, OMERACT- 
OARSI responder index, and quality of life (QoL). An SR 
included the change in joint space width and cartilage 
volume.31
HA compounds were extensively analysed in compar-
ison mostly against IA placebo followed by IA GC. 
Compared with the former and according to Cohen’s 
criteria,21 the effect sizes observed for the intervention 
on pain and function were small and further reduced 
to no effect when pooling large- blinded RCTs only. An 
SR analysed the OMERACT- OARSI response and found 
that patients treated with HA were more likely to achieve 
such a response than those receiving placebo (RR, 1.11 
(1.01 to 1.20)).30 Likewise, when compared vs IA GC, 
the effect sizes of the intervention were small on pain 
and function. Of note, one study favoured IA GC in the 
1- week to 2- week assessment and HA from the 7–10 weeks 
until the 17- week to 29- week evaluations.48 In other SRs, 
there were no differences between groups in most RCTs 
analysed, although pooled OMERACT- OARSI responses 
reached statistical significance (RR, 1.15 (1.02 to 1.30)).30 
Finally, one SR compared HA compounds and showed 
an increasing effect with increased molecular weight 
(MW).22 Of note, the number of studies included was 
rather low and no differences were seen in QoL.
Most SRs of HA reported moderate to high hetero-
geneity between studies, as well as publication bias and 
other biases, mostly concerning inadequate blinding, 
allocation concealment, and reporting.
Against placebo, GC compounds showed small to 
moderate effect sizes for pain and function in the short- 
term (until 3 months), and no differences in QoL, stiff-
ness or joint space width.23 Among GC compounds, MPA 
shows a faster onset of effect on pain and function than 
TA or TH at 6 weeks.34 No differences were detected after 
this time- point as well as in OMERACT- OARSI response 
and no pooled analysis was performed for this compar-
ison. As with HA, authors underline inadequate blinding 
and allocation concealment as possible sources of bias in 
the included RCTs.
PRP was evaluated mostly against HA and, second-
arily, versus placebo. Compared with HA, PRP showed a 
small to null effect on pain, function, and stiffness. Two 
SRs pooled composite scores (WOMAC total score and 
IKDC) and found better responses with PRP than HA 
at 6 and 12 months showing large effects.27 49 Kanchan-
atawan et al25 found an improved EQ- VAS at 12 months 
with PRP.25 For PRP versus placebo, no differences were 
seen in the targeted outcomes, except for the composite 
scores, in which the pooled effect was large; this effect 
disappeared when only high- quality trials were pooled. 
Between- trial heterogeneity was high, in terms of PRP 
composition, endpoints, and comparators. Also, the SRs 
rated included RCTs as with moderate to high risk of bias, 
especially due to inadequate allocation concealment, 
blinding of participants, and outcome assessment.
A network meta- analysis analysed the effect of MSC 
against different comparators, including placebo, HA, 
or IA GC.24 The effect of MSC was moderate to large on 
pain and moderate for the KOOS at 12 months, whereas 
no effect was observed on the WOMAC total score at 6 
months. High- dose adipose- derived MSC showed a longer 
effect. Overall, studies included in this SR were rated as of 
low risk of bias; nonetheless, there was evidence of publi-
cation bias for pain measured by VAS. Unfortunately, 
most branches of the meta- analysis were underpowered 
to draw conclusions on which strategy is better in clinical 
practice.
Hip osteoarthritis
The main results on hip OA are summarised in table 3. 
The most frequent outcomes measured were pain and 
function, the latter measured using the Harris Hip 
Score (HHS) and the OMERACT- OARSI response 
criteria.
PRP was the most frequent compound studied in hip 
OA, and all comparisons were against HA. Almost all 
Figure 1 Flow chart of the overview of systematic reviews 
(SR).
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Rutjes et al7 IC: RCTs
EC: not stated.
HA vs sham or no 
intervention
Primary: pain intensity
Secondary: function, SAEs, 
withdrawal due to AEs
High
Newberry et al22 IC: RCTs, SRs, OS, and CS*
EC: non- English language studies 
and conference abstracts.
HA vs PBO or other 
HA
Primary: delay or avoidance of 
TKR
Secondary: function, QoL, number 
of AE
High
Jüni et al23 IC: RCT of patients treated with 
GC either IA or subacromial.
EC: RCT including only patients 
with inflammatory arthritis
IA GC vs sham, PBO 
or SOC
Primary: pain and function at 4–6 
weeks
Secondary: pain and function at 
subsequent time points, QoL, 
JSN, SAEs, withdrawals due to 
AEs
High
Ding et al24 IC: RCTs reporting ≥1 of the 
outcomes of interest.
EC: use of PRP or MSC+surgery 
or lack of a non- cell- based 
control
MSC vs PBO, HA or 
IAGC
WOMAC, KOOS, VAS, SAEs 
without a prespecified hierarchy
Moderate
Bannuru et al4 IC: RCTs of patients treated with 
HA with data on safety outcomes
EC: non- RCT studies
HA vs HA or PBO Number of AEs, SAEs, 
withdrawals due to AEs without a 
prespecified hierarchy
Moderate
Bannuru et al6 IC: RCTs with data for ≥1 
outcome measure of pain.
EC: studies not including pain 
outcomes of interest
HA vs IAGC Primary: pain according to a 
prespecified hierarchy at different 
time- points
Moderate
Bannuru et al5 IC: RCTs of patients with primary 
KOA with data on ≥2 interventions 
of interest and on ≥1 measure of 





Primary: pain at 3 months 
according to a prespecified 
hierarchy





IC: RCTs of adults with primary 
KOA with ≥1 of the outcomes 
of interest and enough data to 
extract and pool
EC: not stated
PRP vs HA or PBO or 
sham
WOMAC total and subscores, 
Lequesne score, EuroQol- VAS, 
IKDC subjective scores, number 
of AEs without a prespecified 
hierarchy
Moderate
Xu et al26 IC: RCTs with ≥30 randomised 
patients, ≥1 month follow- 
up, quantitative outcome 
assessment, <20% of dropouts
EC: not stated
PRP vs HA, PBO Pain and function (VAS, WOMAC, 
IKDC, Lequesne) without a 
prespecified hierarchy
Moderate
Dai et al27 IC: RCTs comparing PRP 
vs controls for prespecified 
outcomes
EC: not stated
PRP vs HA or PBO Primary: WOMAC pain and 
function scores.
Secondary: WOMAC total score, 
IKDC, Lequesne, frequency of AE
Moderate
Arroll and Goodyear- 
Smith28
IC: PBO- controlled RCTs 
assessing the efficacy of IAGC
EC: not stated
IAGC vs PBO Primary: improvement of 
symptoms
Secondary: pain, response to the 
OA research scale
Moderate
Shen et al29 IC: RCT comparing any PRP vs 
another IAT with ≥12 w follow- up
EC: studies without IA control 
group, other PRP or PRP+surgery
PRP vs HA or PBO Primary: WOMAC pain, function 
and total at 3, 6, and 12 months









Trojian et al30 IC: RCTs in English including 
outcomes of interest at ≥8 and 
<16 weeks.
EC: studies comparing IA GC or 
HA vs surgical procedures
HA vs PBO or IAGC
IAGC vs PBO
OMERACT- OARSI response 
rates, mean change from baseline 
in WOMAC pain, stiffness or 
function, frequency of AE. Without 
hierarchy
Moderate
Gallagher et al31 IC: RCTs with PBO control, ≥12 
m follow- up, data on structural 
changes
EC: not stated
HA or SOC vs PBO† Primary: changes in JSW or 
cartilage volume.
Secondary: WOMAC total score, 
WOMAC pain or VAS pain
Moderate
Di et al32 IC: English- written RCTs
EC: unknown methodology 
or patients with additional 
conditions‡
PRP vs HA Primary: WOMAC, IKDC, KOOS, 
EQ- VAS, Tegner score.





IC: RCTs with ≥1 outcome 
measure on pain or function; 
freely available as full text from 
specified sources§
EC: non- RCT and language other 
than English
HA vs PBO or IAGC VAS pain, Lequesne, WOMAC 
without a prespecified hierarchy
Low
Lo et al33 IC: Blinded—RCTs comparing HA 
(≥3 injections) vs PBO with data 
on pain and 8- week minimum 
follow- up and drop- out rate of 
<50%
EC: not stated




Ali et al36 IC: RCTs, with clinical and 
functional data with any follow- up
EC: studies on animals and 
technical notes
PRP vs HA VAS pain, WOMAC total, and HHS 
without a prespecified hierarchy
Moderate
McCabe et al38 IC: RCTs with patients with HOA 
(clinical and radiographic)
EC: studies without a control 
group
IAGC vs PBO Primary: pain according to a 
prespecified hierarchy
Secondary: WOMAC function, 
Lequesne Index, safety profile
Moderate
Liao et al37 IC: RCTs of patients with primary 
HOA
EC: stated as the opposite to IC
HA vs PBO Primary: self- reported pain 
according to a prespecified 
hierarchy
Secondary: function, OMERACT- 
OARSI responder index
Moderate
Medina- Porqueres41 IC: English or Spanish- written 
studies of PRP applied in isolation 
in ≥1 arm to patients with any 
grade of HOA as per the ACR 
criteria
EC: studies including only 
children or animals; non- OA 
injuries, OA in other joints or 
previous surgery
PRP vs IA control 
(any)
Primary: VAS pain, HHS, and 
WOMAC function.
Secondary: growth factor’s 
concentration, AE and imaging 
evaluations
Low
Ye et al42 IC: RCTs comparing PRP with HA
EC: studies without a control 
group, full- text versions or 
outcomes data
PRP vs HA Primary: WOMAC total score, VAS 
pain, and Harris hip score (HHS)
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RCTs showed no difference between groups at all time 
points except for the study by Ye et al,42 favouring PRP. 
Regarding function, no differences were seen using the 
WOMAC function subscore or the HHS. An SR of four 
RCTs with high heterogeneity and unclear or high risk of 




Leite et al40 IC: RCT with ≥1 of the outcomes 
of interest
EC: RCT comparing HOA vs other 
sites and HA vs non- IA controls
HA vs IA- injection 
comparators
Primary: pain
Secondary: QoL, OMERACT- 




Sun et al45 IC: RCTs comparing IAGC vs no 
or sham injection or SOC
EC: injection volume >0.10 mL 
(classified as IAGC+distention)
IAGC vs sham or 
SOC
Primary: VAS pain
Secondary: passive external 
rotation, abduction, flexion, 
internal rotation,and functional 
scores and frequency of AEs
Moderate
Buchbinder et al43 IC: RCTs of shoulder pain 
comparing IAGC vs PBO, another 
intervention or different IAGC 
dosages
EC: pain duration <3 weeks, RA, 
polymyalgia rheumatica, and 
fracture
IAGC vs PBO, other 
interventions
Pain, ROM, function, strength, and 
return to work or school without a 
prespecified hierarchy
Moderate
Lee et al44 IC: RCT of capsulitis (confirmed 
clinically or by US), clearly 
documenting IC and EC, 
symptom duration and follow- up 
>4 weeks
EC: uncontrolled studies
HA vs SOC Pain, ROM, and function/
disability scores >1 month after 
administration, frequency of AEs 





IC: RCTs of RA patients with knee 
arthritis, enough quality as per the 




vs PBO or TH
Knee circumference, ROM, 
fixed flexion, pain (Likert scale), 
subjective change, knee effusion, 





IC: RCTs of patients with RA and 
knee arthritis
EC: not stated
MPA vs TA, TH, 
prednisolone
Primary: flare time at 24 weeks,
Secondary: patient- reported pain 
and swelling, ROM, frequency of 
AEs
Low
Saito and Kotake47 IC: English or Japanese- written 
RCTs of patients with RA and 
knee arthritis including pain 
assessment
EC: studies with animals or only 
describing the injection technique
HA vs PBO Primary: global pain measured 
with Likert scale at 1 week
Secondary: inflammation 
measured with Likert scale. 
Condition of the knee with Likert 
scale, safety profile
Low
*Only data from RCTs were retrieved for the analyses on the present study.
†Only data for the HA vs PBO comparison were retrieved.
‡Additional conditions included meniscal tears, inflammatory arthritis, among others.
§Free full- texts available from the Warwick University Library or Google Scholar.
¶Articles written in Dutch, English, French, German, or Spanish.
AE, adverse events; CS, case series; EC, exclusion criteria; EQ- VAS, Euro Quality of Life – Visual Analogue Scale; freq of AE, frequency 
of adverse events; GC, glucocorticoids; HA, hyaluronic acid; HHS, Harris Hip Score; HOA, hip osteoarthritis; IA, intra- articular; IAT, intra- 
articular therapies; IC, inclusion criteria; IKDC, International Knee Documentation Committee; JSN, joint space narrowing; JSW, joint 
space width; KOA, Knee Osteoarthritis Index; KOOS, Knee injury and Osteoarthritis Outcome Score ; MPA, methylprednisolone acetate; 
MSC, mesenchymal stem cells; OS, observational studies; PBO, placebo; PRP, platelet- rich plasma; QoL, quality of life; RCT, randomised- 
controlled trials; ROM, range of motion; SAE, serious adverse events; SoC, standard of care; TA, triamcinolone acetonide; TH, triamcinolone 
hexacetonide; TKR, total knee replacement; US, ultrasonography; VAS, Visual Analogue Scale; WOMAC, Western Ontario and McMaster 
Universities Osteoarthritis Index.
Table 1 Continued
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Table 2 Main efficacy results of IAT for knee osteoarthritis
Study Follow- up Outcomes Effect estimate Comments
Hyaluronic acid vs placebo
Rutjes et al7 3 mo Pain Overall (ES, 0.37 (0.28 to 0.46)), favouring HA
Large- blinded RCTs (ES, 0.11 (0.04 to 0.18)), 
favouring HA
Effect size defined as between- 
group differences in means divided 
by the pooled SD at end of follow- 
up.
Minimal clinically important 
difference =
(−0.37 ES)
Function Overall (ES, 0.33 (0.04 to 0.22)), favouring HA
Large- blinded RCTs (ES, 0.09 (0.00 to 0.17)), 
favouring HA
Newberry et al22 1–12 mo Function SMD=0.23 (0.01 to 0.45), favouring HA (WOMAC) Consistent effect in sensitivity 
analysis for too short (<4 weeks) or 
too long (>52 weeks) RCTs
QoL 3 RCTs—no between- group difference (SF-36, 
EuroQol- 5D)
Gallagher et al31 12–24 mo Pain 2 RCTs—no between- group difference (VAS)   
∆ JSW 2 RCTs—no between- group difference
∆ Cartilage volume 1 RCT—favoured HA with 2.60% (1.20–4.10) less 
cartilage volume lost in the medial compartment and 
2.80% (0.90–4.70) less in the lateral compartment
Bannuru et al5 3 mo Pain SMD, 0.34 (Cr I, 0.26 to 0.42), favouring HA MA result of a Bayesian hierarchical 
random- effects model for mixed 
multiple treatment comparisons
Function SMD, 0.3 (Cr I, 0.20 to 0.40), favouring HA
Stiffness SMD, 0.23 (Cr I, 0.13 to 0.34), favouring HA
Trojian et al30 2–6 mo Pain SMD, 0.19 (0.06 to 0.32), favouring HA (WOMAC) NMA. SMD refers to Hedges’ g
Results obtained for the time of best 
response
No publication bias
Function SMD, 0.19 (0.05 to 0.32), favouring HA (WOMAC)
Stiffness SMD, 0.12 (0.03 to 0.27), favouring HA (WOMAC)
O- O Resp RR, 1.11 (1.01 to 1.20), favouring HA
Trigkilidas and 
Anand35
1–6 mo Pain 5 RCTs—no between- group difference (VAS) No pooled analysis
7 RCTs—favoured HA (VAS) (small effect)
Function 5 RCTs—no between- group difference (WOMAC, 
Lequesne)
7 RCTs—favoured HA (WOMAC) (small effect, 
Lequesne)
Lo et al33 2–12 mo Pain Overall, SMD=0.32 (0.17 to 0.47) Evidence of publication bias
Excluding high MW, SMD=0.19 (0.10 to 0.27)
Hyaluronic acid vs glucocorticoids
Bannuru et al 6 1–2 wk Pain ES, 0.39 (0.12 to 0.65), favouring IAGC ES: refers to Hedges’ g corrected for 
small samples
Effects remained consistent after 
multivariable and sensitivity analysis
3–6 wk ES, −0.01 (−0.23 to 0.21), no between- group 
difference
7–10 wk ES, 0.22 (0.05 to 0.49), favouring HA
11–16 wk ES, 0.35 (0.03 to 0.66), favouring HA
17–29 wk ES, 0.39 (0.18 to 0.59), favouring HA
Bannuru et al 5 3 mo Pain SMD, 0.02 (Cr I, −0.12 to 0.17), no between- group 
difference
NMA
Function SMD, 0.24 (Cr I, 0.06 to 0.43), favouring HA
Stiffness SMD, 0.20 (Cr I, 0.0 to 0.41), no between- group 
difference
Trojian et al30 4–40 mo Pain ES, −0.06 (−0.28 to 0.16), no between- group 
difference
NMA
SMD refers to Hedges’ g
Results retrieved at the time of best 
response
No publication bias
Function ES, −0.29 (−0.53 to −0.05), favouring HA
Stiffness ES, −0.17 (−0.50 to 0.16), no between- group 
difference
O- O Resp RR, 1.15 (1.02 to 1.30), favouring HA
Trigkilidas and 
Anand35
1–6 mo Pain 1 RCT—favoured HA at 6 months (VAS) No pooled analysis
Function 1 RCT—no between- group difference
Hyaluronic acid compounds comparison
Continued
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Study Follow- up Outcomes Effect estimate Comments
Newberry et al 22 1–12 mo Function 1 RCT—LMW vs MMW. SMD, −0.326 (−0.52 to 
−0.13), favouring MMW All comparisons using the WOMAC 
function subscale
No pooled analysis
*Results of the same study54 at 2 
time- points
1 RCT—LMW vs HMW. SMD, 0.053 (−0.66 to 0.77), 
no difference
1 RCT—LMW vs HMW. SMD, −0.882 (−1.09 to 
−0.68), favouring HMW
1 RCT—MMW vs HMW. SMD, −0.01 (−0.21 to 0.19), 
no difference
3 mo QoL 1 RCT*—LMW vs HMW, favouring LMW (EuroQol- 5D)
12 mo 1 RCT*—LMW vs HMW, favouring HMW (EuroQol- 5D)
1 RCT—LMW vs HMW. No between- group difference 
(SF-36)
Glucocorticoids vs placebo
Jüni et al23 2 wk Pain SMD −0.48 (−0.70 to −0.27), favouring IAGC For pain and function, effects were 
reduced in large trials (>50 patients/
arm)
2 mo SMD −0.41 (−0.61 to −0.21), favouring IAGC
3 mo SMD −0.22 (−0.44 to 0.00), no between- group 
difference
6 mo SMD −0.07 (−0.25 to 0.11), no between- group 
difference
2 wk Function SMD −0.43 (−0.72 to −0.14), favouring IAGC
2 mo SMD −0.36 (−0.63 to −0.09), favouring IAGC
3 mo SMD −0.13 (−0.37 to 0.10), no between- group 
difference
6 mo SMD 0.06 (−0.16 to 0.28), no between- group 
difference
6 mo QoL SMD −0.01 (−0.30 to 0.28), no between- group 
difference
JSW SMD −0.02 (−0.49 to 0.46), no between- group 
difference
Arroll and Goodyear- 
Smith28
2 wk Pain WMD −16.47 (−22.92 to −10.03), favouring IAGC †Pooling studies with the highest 
dose2 wk Improvement of 
symptoms
RR 1.66 (1.37 to 2.01), favouring IAGC
3–4 mo RR 2.09 (1.20 to 3.65), favouring IAGC†
Bannuru et al 5 3 mo Pain SMD, 0.32 (Cr I, 0.16 to 0.47), favouring IAGC NMA
Function SMD, 0.06 (Cr I, −0.13 to 0.26), no between- group 
difference





1–6 mo Pain 1- RCT—MPA vs TH. No between- group difference 
(VAS)
*Results of the same study at 2 time- 
points
¥Results of the same study at 2 
time- points
No pooled analysis
6 wk 1- RCT*—MPA vs TA vs prednisolone, favouring MPA 
(VAS)
3 mo 1- RCT*—MPA vs TA vs prednisolone, no between- 
group difference
1 month 1- RCT¥—MPA vs TH, favouring MPA (VAS)
2 mo 1- RCT¥—MPA vs TH. No between- group difference 
(VAS)
1–6 mo Function 1- RCT—MPA vs TH. No between- group difference 
(WOMAC)
1–3 mo 1- RCT—MPA vs TA vs prednisolone. No difference 
(Lequesne)
2 mo 1- RCT—MPA vs TH. No between- group difference 
(Lequesne)
2 mo O- O Response 1- RCT—MPA vs TH. No between- group difference
Platelet- rich plasma vs placebo
Table 2 Continued
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Study Follow- up Outcomes Effect estimate Comments
Xu et al49 6 mo Composite scores# Overall, SMD −2.13 (−3.29 to −0.98), favouring PRP #Effects of pooled results from 
WOMAC and IKDC scores
Dai et al27 6–12 mo Pain 1 RCT—favoured PRP (WOMAC)   
Function 1 RCT—favoured PRP (WOMAC)
Kanchanatawan et 
al25
6–12 mo Pain No between- group difference (WOMAC)   
Function No between- group difference (WOMAC)
Stiffness No between- group difference (WOMAC)
Platelet- rich plasma vs hyaluronic acid
Xu et al26 6 mo Composite scores¶ Overall, SMD = −0.85 (−1.43 to −0.28) favouring PRP ¶ Refers to observed effects when 
pooling results from WOMAC and 
IKDC scores
High- quality RCTs, SMD = −0.09 (−0.30 to 0.11). No 
difference
Pain SMD=0.35 (−0.36 to 1.06) (VAS). No difference
Function MD=−0.20 (−1.00 to 0.60) (Lequesne). No difference
3 mo WOMAC total MD=−7.10 (−17.02 to 2.82). No between- group 
difference
12 mo MD=−8.93 (−27.56 to 9.71). No between group 
difference
Shen et al29 3–12 mo Pain MD=−3.77 (−5.07 to −2.47), favouring PRP (WOMAC) Results obtained from pooling 
outcomes at 3, 6, and 12 monthsFunction MD=−13.91 (−18.53 to −9.28), favouring PRP 
(WOMAC)
WOMAC total MD=−17.39 (−22.32 to −12.46), favouring PRP
Dai et al27 6 mo Pain MD=−1.54 (−4.27 to 1.20). No between- group 
difference
  §Results from pooling WOMAC 
total, IKDC,EQ and Lequesne 
Index12 mo MD=−2.83 (−4.26 to −1.39), favouring PRP
6 mo Function MD=−4.39 (−10.51 to 1.74). No between- group 
difference
12 mo MD=−12.53 (−14.58 to −10.47), favouring PRP
6 mo Composite scores§ SMD=0.68 (−0.04 to 1.41). No between- group 
difference
12 mo SMD=1.05 (0.21 to 1.89), favouring PRP
Kanchanatawan et 
al25
6–12 mo Composite scores§ MD= −15.4 (−28.6 to −2.30), favouring PRP (WOMAC 
total)
§Results for WOMAC total and IKDC 
reached the prespecified MCID
MD=8.83 (5.88 to 11.78), favouring PRP (IKDC)
Pain No between- group difference (WOMAC)
Function No between- group difference (WOMAC)
Stiffness No between- group difference (WOMAC)
QoL MD=7.37 (4.33 to 10.05), favouring PRP (EQ- VAS)
Di et al32 1–12 mo Pain 5 RCTs—favoured PRP (VAS, WOMAC) No pooled analysis
1 RCT—no between- group difference (VAS)
Function 3 RCTs—favoured PRP (WOMAC, Lequesne, KOOS)
3 RCTs—no between- group difference (WOMAC, 
Lequesne, etc)
Stiffness 2 RCTs—favoured PRP (WOMAC)
2 RCTs—no between- group difference (WOMAC)
O- O Response 1 RCT—favoured PRP
QoL 3 RCTs—no between- group difference (EQ- VAS, SF-
36)
Mesenchymal stem cells vs controls
Table 2 Continued
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No differences were observed for pain, function nor 
OMERACT- OARSI response between HA and placebo or 
MPA. McCabe et al,38 on the contrary, reported an OR=7.8 
(2.7–22.8) for reaching an OMERACT- OARSI response 
in patients treated with IA GC versus placebo. The latter 
SR included four RCTs, three of which showed better 
results in function (activities of daily life and WOMAC 
function subscore). All studies were deemed as having a 
low to moderate risk of bias and no evidence of publica-
tion bias.
Shoulder capsulitis
Table 4 summarises the main efficacy results for shoulder 
capsulitis. Pain was only measured using VAS and func-
tion evaluated by the range of motion (ROM). Addition-
ally, specific composite scores such as the Shoulder Pain 
and Disability Index (SPADI), the American Shoulder 
and Elbow Surgeons score and (ASES), and the Constant 
score were applied. HA and IAGC were the interventions 
evaluated and most comparisons were against placebo. 
One SR44 assessed the former and found no differences 
for pain or function. On the contrary, IAGC were evalu-
ated in two SRs and a small effect was observed favouring 
the intervention on pain, ROM, and the SPADI whereas 
no differences were seen for the ASES and the Constant 
score.
Overall, there was high heterogeneity between 
studies regarding injection techniques dose and type of 
compound as well as comparators. Major sources of bias 
were inadequate blinding of participants and personnel, 
inadequate allocation concealment, and possible small 
study bias.
Rheumatoid arthritis
The main results of IAT in RA are also shown in table 4. 
Outcomes varied widely and included pain, ROM, global 
inflammation, number of flares, and grip strength. HA, 
IAGC, and yttrium synovectomy were the interventions 
assessed. Saito and Kotake47 observed better perfor-
mance of HA over placebo for pain, global inflammation, 
and self- reported effectiveness. Brazilian Medical Associa-
tion34 found no differences in the number of flares, ROM, 
morning stiffness, grip strength, Ritchie articular index, 
or thermography index, between MPA, TA, or TH. In one 
RCT, TH performed better in pain (VAS) at 1 week of 
follow- up but there were no between- group differences 
at 2 to 6 weeks. Finally, Heuft- Dorenbosch et al46 found 
no differences in pain between yttrium synovectomy 
and placebo or IAGC, whereas the former performed 
better in ROM and knee circumference (1 RCT) versus 
placebo. Conversely, ROM was best improved in the 
IAGC- treated group (vs yttrium synovectomy). Two out 
of three SRs assessing treatments for RA were deemed as 
of low quality and included a very low number of RCTs 
with evidence of small study bias and unclear or inade-
quate allocation concealment, as well as participant and 
provider blinding.
Safety of intra-articular treatments
Twenty- two SRs provided data on safety (table 5). In most 
cases, the outcome reported was the frequency of AEs 
(any), while some articles also analysed SAEs and with-
drawals due to AEs.
HA compounds were compared against placebo in a 
network meta- analysis specifically designed to assess safety 
in KOA.4 No between- group differences were observed 
for any AE but local reactions and withdrawal due to AEs 
favoured placebo versus HA. Other SRs analysing HA 
compounds reported similar results for any AEs, SAEs, 
and withdrawals due to AE.
Of note, Rutjes et al7 found a higher risk of local reac-
tions, SAEs, and withdrawals with HA versus sham or no 
interventions. In this SR, the pooled RR of SAEs from 
14 RCTs was 1.41 (1.02 to 1.97), consistent when pooling 
only large- blinded RCTs (RR=1.55 (1.07 to 2.24)). Said 
SAEs consisted of 27 events in visco supplementation 
patients versus 21 in control patients. Most frequent 
disorders were related to the gastrointestinal system (2 
vs 8), cardiovascular system (5 vs 2), cancer (6 vs 0), and 
musculoskeletal system (4 vs 2). The authors underlined 
that the poor quality of reporting safety data of the RCTs 
analysed made the understanding of the probable causes 
for these observations difficult.
Study Follow- up Outcomes Effect estimate Comments
Ding et al24 6 mo Composite scores SMD=−0.36 (−0.90 to 0.18). No difference (WOMAC 
total) vs controls
NMA.
Controls include HA, PBO, and GC.
High- dosage adipose- derived MSC 
showed a longer effect
12 mo SMD=0.68 (0.07 to 1.30), favouring MSC (KOOS) vs 
controls
12 mo Pain SMD= −1.05 (−1.46 to −0.64), favouring MSC vs 
controls
Results are ordered by compounds and quality. The colour of the cell denotes quality: the darker the higher the quality. All effect sizes (ESs) are presented as a 
point estimate (95% CI) unless otherwise noted.
Cr I, credible intervals; EQ- VAS, Euro Quality of Life – Visual Analogue Scale; EuroQol- 5D, Euro Quality of Life – 5 Dimension questionnaire; GC, glucocorticoids; 
HA, hyaluronic acid; HMW, high molecular weight; IAGC, intra- articular glucocorticoids; IAT, intra- articular therapies; IKDC, International Knee Documentation 
Committee; ∆JSW, change in joint space width; KOOS, Knee injury and Osteoarthritis Outcome Score; LMW, low molecular weight; MCID, minimal clinically 
important difference; MD, mean difference; MMW, medium molecular weight; mo, months; MPA, methylprednisolone acetate; MSC, mesenchymal stem cells; NMA, 
network meta- analysis; O- O Resp, OMERACT- OARSI Responder Index; PBO, placebo; PRP, platelet- rich plasma; QoL, quality of life; RCT, randomised controlled 
trials; RR, relative risk; SF-36, Short Form 36 health survey; SMD, standardised mean difference; TA, triamcinolone acetonide; TH, triamcinolone hexacetonide; 
VAS, Visual Analogue Scale; wk, weeks; WMD, weighted mean difference; WOMAC, Western Ontario and McMaster Universities Osteoarthritis Index.
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Table 3 Main efficacy outcomes for hip osteoarthritis
Study Comparison Follow- up Outcomes Effect estimate Comments
Hyaluronic acid
Leite et al40 HA vs PBO, PRP, 
MPA
1–12 months Pain No between- group difference vs 
PRP (VAS)
  
3 months No between- group difference vs 
PBO (VAS)
1–12 months O- O Resp No between- group difference vs 
MPA
3 months No between- group difference vs 
PBO
Liao et al37 HA vs PBO or 
IAGC
2 weeks Pain SMD= –0.18 (–0.47 to 0.10), no 
between- group difference
Data on pain was 
obtained as per a 
previously described 
hierarchy.55
Analyses use IAGC and 
PBO as comparators.
4 weeks SMD= –0.14 (–0.46 to 0.18), no 
between- group difference
2–6 months SMD= –0.14 (–0.46 to 0.18), no 
between- group difference
2 weeks Function SMD=−0.14 (−0.52 to 0.24), no 
between- group difference
4 weeks SMD=−0.16 (−0.34 to 0.03), no 
between- group difference
2–6 months SMD=−0.28 (−0.60 to 0.05), no 
between- group difference
Glucocorticoids
McCabe et al38 IAGC vs PBO 1–3 months Pain SMD=−1.90 (−4.07 to 0.26), no 
between- group difference
Comparisons vs PBO
2 months O- O Resp OR=7.8 (2.7–22.8), favouring 
IAGC
Function 3 RCTs—favoured IAGC (ADL, 
WOMAC function)
1 RCT—no between- group 
difference
ROM 1 RCT—favoured IAGC





PRP vs HA 1 month Pain MD=−0.58 (−1.82 to 0.65) (VAS), 
no difference
All comparisons vs HA
6 months MD=0.20 (−1.36 to 1.77) (VAS), 
no difference
12 months MD=−0.42 (−1.80 to 0.96) (VAS), 
no difference
2–12 months Function 3 RCTs—no between- group 
difference (HHS)
1 RCT—favoured HA (WOMAC)
1 RCT—no between- group 
difference (WOMAC)
Stiffness 1 RCT—favoured HA (WOMAC)
1 RCT—no between- group 
difference (WOMAC)
Continued
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Results on withdrawal due to AEs were obtained 
after pooling 23 RCTs, but the effect disappeared when 
restricting the analysis to large- blinded RCTs. One SR 
reported significant differences between HA and IA GC, 
favouring the latter for joint pain after injection (17% vs 
3.2%).30
Safety results for HA in HOA were also reassuring, 
with no between- group differences observed for any of 
the outcomes of interest, except for an episode of septic 
arthritis, reported in an RCT (vs placebo) included in 
the SR by Liao et al.37 Other SRs of HA for shoulder 
capsulitis and RA also did not report differences between 
groups.44 47
IA GC behaved similarly to placebo without any differ-
ences in safety outcomes in all SRs included in this over-
view for KOA, HOA, shoulder capsulitis, or RA. Of note, 
Juni et al23 also did not find differences between IAGC 
versus sham or no intervention, on any AEs, SAEs, or with-
drawals due to AEs. Also, this trend remained consistent 
when comparing different IA GC compounds and doses. 
In the same line, SRs on PRP for KOA and HOA showed 
similar safety profiles than its comparators (mostly HA), 
except for an RCT in the SR by Medina- Porqueres et al41 
that found significantly more pain after injection in the 
PRP group. Finally, results for MSC on KOA were in line 
with the previously described.
DISCUSSION
To our knowledge, this is the first overview of published 
SR summarising the efficacy and safety of the most 
frequently used IA treatments. Based on the available 
literature, we assessed the performance of five treatment 
groups in four arthropathies. Most studies evaluated the 
effects of IAT on KOA and HOA. The average quality 
of the SRs was moderate, and high heterogeneity was a 
constant, prompting authors to be conservative when 
concluding. Most compounds evaluated presented a 
small effect for relieving pain and improving function, 
but with inconsistent results and a high risk of bias in 
most cases. Regarding safety, the frequency of AEs was 
low, and only a few SAEs were reported, without clear 
differences between the different injectables assessed.
HA compounds showed a modest effect on pain and 
function in KOA and RA and no effect on HOA or shoulder 
capsulitis. Of note, the effects seen for the former, despite 
Study Comparison Follow- up Outcomes Effect estimate Comments
Ye et al
42
PRP vs HA 2 months Pain WMD=−0.38 (−0.61 to −0.14), 
favouring PRP (vs HA)
All comparisons vs HA
6 months WMD=−0.14 (−0.40 to 0.12), no 
between- group difference
12 months WMD=−0.0 (−0.34 to 0.12), no 
between- group difference
2 months Function WMD=2.07 (−2.66 to 6.79) (HHS), 
no difference
6 months WMD=2.78 (−6.64 to 12.20) 
(HHS), no difference
12 months WMD=0.71 (−6.33 to 7.75) (HHS), 
no difference
6 months WMD=−2.84 (−6.25 to 0.57) 
(WOMAC), no difference
12 months WMD=−3.13 (−6.62 to 0.36) 
(WOMAC), no difference
Ali et al36 PRP vs HA 2–12 months Pain 1 RCT—favoured PRP (VAS) All comparisons vs HA
2 RCTs—no between- group 
difference (VAS)
Function 1 RCT—no between- group 
difference (HHS)
1 RCT—favoured PRP (WOMAC)
1 RCT—no between- group 
difference (WOMAC)
All effect sizes are presented as the point estimate (95% CI) unless otherwise stated.
ADL, activities of daily life; HA, hyaluronic acid; HHS, Harris Hip Score; IAGC, intra- articular glucocorticoids; MD, mean 
difference; MPA, methylprednisolone acetate; O- O Resp, OMERACT- OARSI Responder Index; PBO, placebo; PRP, platelet- 
rich plasma; RCT, randomised- controlled trials; SMD, standardised mean difference; VAS, Visual Analogue Scale; WMD, 
weighted mean difference; WOMAC, Western Ontario and McMaster Universities Osteoarthritis Index.
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Table 4 Main efficacy outcomes for shoulder capsulitis and rheumatoid arthritis




HA vs PBO 3–6 months Pain 1 RCT—no between- group difference 
(VAS)
  
Function 1 RCT—no between- group difference 
(Constant score)




IAGC vs PBO 4 weeks Pain 1 RCT—no between- group difference 
(VAS) (vs PBO)
  
6 weeks 1 RCT—no between- group difference 
(VAS) (TA 40 mg vs 10 mg)
4 weeks Function 1 RCT—no between- group difference 
(ROM)
6 weeks 1 RCT—favour higher dose (ROM) (TA 
40 mg vs 10 mg)
4 weeks Success 
frequency
1 RCT—no between- group difference
Sun et al45 IAGC vs PBO 4–6 weeks Pain MD=1.28 cm (0.75 to 1.82) (VAS), 
favouring IAGC
Comparisons with 





improved in IAGC- 
treated patients (vs 
PBO) at all 3 time- 
points
12–16 weeks MD=1.00 cm (0.47 to 1.52) (VAS), 
favouring IAGC
24–26 weeks MD=0.65 cm (0.19 to 1.10), favouring 
IAGC
4–6 weeks Composite 
scores
MD=16.62 (11.16 to 22.09), favouring 
IAGC (SPADI)
12–16 weeks MD=13.46 (8.15 to 18.77), favouring 
IAGC (SPADI)
24–26 weeks MD=9.91 (2.32 to 17.50), favouring 
IAGC (SPADI)
4–6 weeks MD=5.30 (–4.38 to 14.98), no 
difference (ASES)
12–16 weeks MD=12.20 (2.55 to 21.85), favouring 
IAGC (ASES)
24–26 weeks MD=7.30 (–2.02 to 16.62), no 
difference (ASES)
12–16 weeks MD=5.70 (–0.59 to 11.99), no 
difference (Constant score)
4–6 weeks Function MD=20.26° (9.70 to 30.83) favouring 
IAGC (ROM—Int Rotation)
12–16 weeks MD=0.81° (0.18 to 1.44) favouring 
IAGC (ROM—Int Rotation)





HA vs PBO 1 week Pain RR=1.64 (1.14 to 2.35), favouring HA Outcomes were 
measured with 
a Likert scale 






RR=1.61 (1.34 to 1.92), favouring HA
Overall 
effectiveness
RR=1.50 (1.14 to 1.97), favouring HA
Continued
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remaining, were reduced when pooling only large studies 
with low risk of bias or longer follow- up.5 7 22 30 31 35 HA 
showed a better OMERACT- OARSI response in KOA 
versus placebo and IA GC.5 6 30 35 Only one SR assessed the 
effects of different HA compounds in KOA and observed 
differences in favour of those with higher MW on the 
WOMAC, but authors acknowledge there were too few 
studies to conclude about the superiority of one group 
over another.22 Regarding its effect on RA, it should be 
noted that the only SR addressing this topic included five 
RCTs performed in Asian populations and efficacy was 
measured using scales that are seldom used, and evidence 
of publication bias, so the results should be interpreted 
with caution.47
The body of evidence of IA GC in the target diseases 
was smaller compared with that of HA, very likely due 
to greater industry support for HA. Similarly, its effect 
versus placebo on pain and function in KOA ranged 
from a small, but significant, short- term effect to no 
effect. In contrast, IA GC showed a better, although 
modest, performance on HOA and shoulder capsulitis. 
Likewise, no evidence of an effect on QoL or joint space 
narrowing was observed. One SR compared different 
IAGC compounds in KOA and found no differences in 
the outcomes of interest, except for a longer effect of 
MPA compared with TH.34
Although IA GC have been among the most widely 
used tools for managing inflammatory arthritis for years, 
our search strategy did not retrieve any SR including 
RCTs comparing them against PBO. Only one study eval-
uated three different GC compounds in RA and found 
no differences between them in all outcomes evaluated 
except for pain VAS at 1 week of follow- up in which the 
analysis favoured TH.
SRs including RCTs on PRP are still limited and our 
strategy only retrieved articles assessing its performance 
on KOA and HOA. There were only a few RCTs included 
and substantial overlapping between SRs. Overall, better 
performance for pain and function was seen in KOA with 
large effects reported when pooling composite scores 
compared with placebo or HA.25 27 29 32 39 This trend 
was not present in HOA, with only a few RCTs showing 
modest effects on pain.36 39 41 42 One consistent observa-
tion between studies was that the PRP effect lasted longer 
than its comparators (mostly HA).




MPA vs TH, TA 
or prednisolone
4–24 weeks Pain 1 RCT—MPA vs TA. No between- 
group difference (VAS)
#Results of the 
same study at 2 
time- points1 week 1 RCT—MPA vs TH vs prednisolone. 
Favour TH (VAS)#
2–6 weeks 1 RCT—MPA vs TH vs prednisolone. 
No difference (VAS)#
4–24 weeks N° of flares 1 RCT—MPA vs TA. No between- 
group difference
ROM 1 RCT—MPA vs TA. No between- 
group difference
1–6 weeks Morning stiffness 1 RCT—MPA vs TH vs prednisolone. 
No difference
















6–12 months Pain 2 RCTs—no between- group difference No differences in 
any other outcome 
(subjective change, 
knee effusion, etc)
6 months ROM 1 RCT—favouring yttrium 
synovectomy (vs PBO)
12 months 1 RCT—favouring TA (vs yttrium 
synovectomy)
12 months Knee 
circumference
1 RCT—favouring yttrium (vs PBO)
All effect sizes are presented as the point estimate (95% CI) unless otherwise stated.
ASES, American Shoulder and Elbow Surgeons score; HA, hyaluronic acid; IAGC, intra- articular glucocorticoids; MD, mean difference; 
MPA, methylprednisolone acetate; PBO, placebo; RCT, randomised controlled trials; ROM, range of motion; Int Rotation, internal 
rotation; RR, relative risk; SPADI, Shoulder Pain and Disability Index; TA, triamcinolone acetonide; TH, triamcinolone hexacetonide; VAS, 
Visual Analogue Scale.
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Table 5 Main safety outcomes of all included compounds
Study Comparison Follow- up Outcomes Effect estimate Comments
Knee osteoarthritis
Bannuru et al4 HA vs PBO 4–52 weeks Any AEs No between group 
differences (vs PBO)
NMA specifically 
aimed at analysing 
safety.
Comparisons are 
between PBO and 
all RCTs of individual 
HA products.
No pooled analysis 
of HA as a group 
was carried on.
Local reactions Analyses favoured 
PBO for 2/17 products 
assessed
Withdrawal due to AEs Analyses favoured 
PBO for 1/11 products 
assessed
Bannuru et al5 HA vs PBO
HA vs IAGC
IAGC vs PBO
2–6 months Any AE HA vs PBO: 16 (54.6) vs 
21.7 (56.0)
No pooled analysis 
was carried on. 
Results are median 
(IQR) of event rates, 
%
HA vs IAGC: 0.0 (64.6) vs 
5.5 (57.2)
IAGC vs PBO: No data
SAEs HA vs PBO: 0 (0.9) vs 
0 (0)
HA vs IAGC: 0.0 (2.0) vs 
0.0 (4.3)
IAGC vs PBO: No data
Withdrawal due to AEs HA vs PBO: 0.9 (3.9) vs 
1.0 (2.6)
HA vs IAGC: 1.9 (3.7) vs 
2.7 (6.0)
IAGC vs PBO: 0.0 (3.5) 
vs 0.0 (1.7)
Local reactions HA vs PBO: 8.4 (14.4) vs 
4.7 (16.1)
HA vs IAGC: 2.2 (21.8) vs 
3.0 (9.1)
IAGC vs PBO: 3.3 (17.9) 
vs 6.9 (8.0)
Septic joint HA vs PBO: 0 (0) vs 0 (0)
HA vs IAGC: 0 (0) vs 0 (0)
IAGC vs PBO: 0 (0) vs 
0 (0)
Newberry et al22 HA vs PBO 1–12 months Local reactions OR 0.70 (0.48 to 1.03). 
No between- group 
difference
  
Joint pain OR 0.83 (0.60 to 1.15). 
No between- group 
difference
Serious join reactions OR 0.77 (0.25 to 2.31). 
No between- group 
difference
Other AE OR 1.26 (0.94 to 1.68). 
No between- group 
difference
Other SAE OR 0.62 (0.23 to 1.57). 
No between- group 
difference
Continued
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Study Comparison Follow- up Outcomes Effect estimate Comments
Trojian et al30 HA vs PBO 2–6 months Joint pain 1 RCT—HA vs IAGC 
—17% vs 3.2%, p<0.05
Some RCTs did 
not report data on 
withdrawal due to 
AE
IAGC vs PBO 10 RCT—no between- 
group difference
HA vs IAGC Any AE 11 RCTs—no between- 
group difference
  SAEs 11 RCTs—no between- 
group differences
  Withdrawal due to AEs 4 RCTs—no between- 
group differences
Rutjes et al7 HA vs sham or no 
intervention
3 months Local reactions RR=1.34 (1.13 to 1.60) †RR for SAE 
resulted from 
pooling 14 RCTs. 
¥RR for withdrawals 
resulted from 
pooling 23 RCTs. 
The effect was 
not maintained 
when pooling large 
unblinded RCTs.
Any AE RR=1.04 (0.99 to 1.09). 
No between- group 
differences
SAEs† Overall, RR=1.41 (1.02 
to 1.97)
Large blinded RCTs, 
RR=1.55 (1.07 to 2.24)
Withdrawal due to 
AEs¥
RR=1.33 (1.01 to 1.74)
Jüni et al23 IAGC vs sham or 
no intervention
2 weeks to 6 
months
Any AE RR=0.89 (0.64 to 1.23)   
SAEs RR=0.63 (0.15 to 2.67)
Withdrawal due to 
AEs¥
RR=0.33 (0.05 to 2.07)
Brazilian Medical 
Association34
MPA vs TA or TH 
or BP
4–24 weeks Any AE 1 RCT—o AE reported   
1 RCT—no data on AE
1 RCT—no between- 
group differences
Shen et al29 PRP vs HA or 
IAGC or PBO
3–12 months Any AE RR=1.40 (0.80 to 2.45). Comparisons were 
mainly with HASAE No SAEs were identified
Kanchanatawan et 
al25
PRP vs HA or 
PBO
6–12 months Any AE RR=0.85 (0.57 to 1.28) 
(vs HA)
  
RR=6.30 (0.34 to 117.48) 
(vs PBO)
SAEs No data reported
Dai et al27 PRP vs HA or 
PBO
6–12 months Any AE RR=0.63 (0.20 to 1.98) 
(vs HA)
  
RR=2.63 (0.04 to 158.93) 
(vs PBO)
SAEs No data reported
Di et al32 PRP vs HA 1–12 months Any AE 1 RCT—significantly 
more pain in PRP group
  
1 RCT—reported no AEs
1 RCT—o safety data 
reported
4 RCT—no between- 
group differences
SAE 5 RCT—reported no 
SAEs
Ding et al24 MSC vs PBO or 
HA or IAGC
6–12 months Any AE No data reported   
SAE OR=1.95 (0.89 to 4.26)
Table 5 Continued
Continued
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MSCs appear to be a potentially promising treatment 
for OA, but SRs including RCTs are scarce. Our strategy 
only retrieved one SR in KOA that met our inclusion 
criteria.24 Moderate to large effects were seen for KOOS 
and pain, respectively, that lasted until 12 months of 
follow- up. However, the data in which to draw firm conclu-
sions were scarce. Finally, our thorough search retrieved 
one SR that evaluated radioisotopic synovectomy for RA 
in which a modest effect was seen over placebo, whereas 
it was outperformed by IA GC for some outcomes, such 
as ROM.46
Although we are aware that safety is best studied in large 
long- term observational studies, we retrieved informa-
tion regarding AEs from the SRs of RCTs. Of note, many 
of them did not report on this aspect.5 6 30 31 33 35–37 39 43 44 
The SR specifically aimed at analysing this for individual 
HA compounds versus different comparators found a 
frequency of any AE remarkably low and no increased 
risk or only for local reactions.4 7
Striking differences were seen regarding the number 
of published articles for the different compounds studied 
with HA the intervention which has been most widely 
Study Comparison Follow- up Outcomes Effect estimate Comments
Hip osteoarthritis
Leite et al40 HA vs PBO or 
MPA
1–12 months Any AE RR=1.07 (0.78 to 1.48) 
(vs PBO)
  
RR=2.24 (0.24 to 20.85) 
(vs MPA)
3 RCTs—no between- 
group differences. (vs 
PBO)
Liao et al37 HA vs PBO 2 weeks to 6 
months
Any AE 4 RCTs—no between- 
group differences
  
SAE 1 RCT—one septic 
arthritis episode on the 
HA group
Withdrawal due to AEs 1 RCT—no between- 
group differences
McCabe et al38 IAGC vs PBO 1–3 months Any AE 2 RCTs—none reported   




PRP vs HA 1–12 months Any AE 1 RCT—more pain in 
PRP group (p<0.05)
  
1 RCT—reported one 
sup haematoma on PRP 
group
Ye et al42 PRP vs HA 2–12 months Any AE RR=0.95 (0.40 to 2.24)
Shoulder capsulitis
Lee et al44 HA vs PBO 3–6 months Any AE 2 RCTs—no AE reported   
2 RCTs—no data on AE
Buchbinder et al43 TA 40 mg vs TA 
10 mg
4–6 weeks Any AE No between- group 
differences
  
Sun et al45 IAGC vs PBO 4–26 weeks Any AE 3 RCTs—no between- 
group differences
  
5 RCTs—no data on AE
Rheumatoid arthritis
Saito and Kotake47 HA vs PBO 1 week Any AE RR=0.98 (0.94 to 1.02)   
Silvinato
and Bernardo34
MPA vs TH or TA 1–6 months Any AE 1 RCT—no AE reported   
1 RCT—no data on AE   
All effect sizes are presented as the point estimate (95% CI) unless otherwise stated.
AE, adverse events; HA, hyaluronic acid; IAGC, intra- articular glucocorticoids; MPA, methylprednisolone acetate; MSC, mesenchymal 
stem cells; NMA, Network Meta- analysis; PBO, placebo; PRP, platelet- rich plasma; RCT, randomised controlledl trials; RR, relative risk; 
SAE, serious adverse events; TA, triamcinolone acetonide; TH, triamcinolone hexacetonide.
Table 5 Continued
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studied to date. However, this was not translated into 
a better quality of evidence, preventing authors from 
drawing firm conclusions regarding many of the studied 
outcomes. Most of the trials included in the different SRs, 
especially the ones of PRP and MSC, were highly hetero-
geneous in terms of the composition of the PRP or the 
kind of MSC and the procedures used to deliver them. 
The overall risk of bias within all SRs in this work was 
high, mostly because of inadequate blinding, allocation 
concealment, selective reporting, or publication bias.
It should be also noted that, even although all 
compounds studied presented modest effect sizes, many 
authors underlined the fact that a proportion of the 
effect may be due to the placebo effect that accompanies 
injections5 23 35; something that should be acknowledged 
when interpreting their results.
This overview of SR has some strengths, such as the 
comprehensive summary of the currently available IAT 
including a large number of RCTs. However, it has some 
limitations. First, including only SRs of RCTs might have 
precluded the analysis of more recent studies still not 
included in said reviews, as well as a deeper evaluation 
of some treatments, such as MSC in OA or GC in inflam-
matory arthropathies. Second, for the most frequent 
diseases affecting the shoulder, SRs usually analyse both 
IA and peri- articular procedures together, which fell 
out of the scope of the present work, thus leading us to 
exclude them. Third, most information analysed in this 
work concerned some frequently assessed outcomes, 
such as pain and function, but only a few studies exam-
ined structural outcomes like joint space narrowing or 
cartilage volume loss, which are currently receiving more 
attention.52 53 Finally, a more thorough search in addi-
tional databases would have been desirable; but given 
the large amount of hits retrieved and the fact that we 
were looking for SRs, the potential selection bias would 
be kept at a minimum.
In summary, the evidence shows that IAT in the most 
frequent arthropathies is well tolerated, with a very low 
frequency of AEs, but only marginally efficacious in the 
short- to- medium- term when compared with placebo. None-
theless, it should be noted that the limited data found 
regarding the efficacy and safety of IAT in inflammatory 
arthropathies prevented us from drawing firm conclusions.
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